1. Shenzhen Keyi Pharmaceutical Holdings Co., Ltd.
Shareholding: 131,778,3 shares, with a shareholding ratio of 66.32%.
ii. Shenzhen hengjian enterprise management partnership (limited partnership)
shareholding: 9,23,8 shares, shareholding ratio: 4.65%.
iii. Shenzhen yuzao enterprise management partnership (limited partnership)
shareholding: 8,16,2 shares, shareholding ratio: 4.3%.
iv. Changjiang Fortune-Kexing Pharmaceutical Staff Strategic Placement Collective Asset Management Plan
Shareholding: 4,967,5 shares, shareholding ratio: 2.5%.
V. CITIC Jiantou Investment Co., Ltd.
Shareholding: 822,4 shares; shareholding ratio: .41%.
VI. Li Yonggang
Shareholding: 8, shares; shareholding ratio: .4%.
VII. Tianji Quantification (Beijing) Capital Management Co., Ltd.-Tianji Exclusive No.12 Private Equity Investment Fund
Shareholding: 478,7 shares, shareholding ratio: .24%.
VIII. Wang Jianyu
Shareholding: 336,9 shares; shareholding ratio: .17%.
IX. Shenzhen Runzeli Investment Co., Ltd.
Shareholding: 38,6 shares; shareholding ratio: .16%.
X. Shu Jie
Shareholding: 291,7 shares; shareholding ratio: .15%.
kexing biopharmaceutical co., ltd. is an innovative biopharmaceutical enterprise mainly engaged in the research, development, production and sales of recombinant protein drugs and microecological agents. it was established on August 22, 1997 and is headquartered in Zhangqiu district, Jinan city, Shandong province.
the company focuses on drug research and development in the fields of antivirus, tumor and immunity, hematology, digestion, degenerative diseases, etc., and successfully landed in science and technology innovation board on December 14th, 22, with the stock code of 688136.
in December, 221, Kexing Bio announced its unaudited financial report for the first half of 221, with sales of $11 billion and net profit of $5.1 billion.
The company has built a complete drug research and development innovation system, covering the ability of drug innovation from drug discovery, pharmaceutical research, preclinical research, clinical research to industrialization. It has three major technical systems, including prokaryotic cell technology, eukaryotic cell technology and microecological viable bacteria technology, and successfully built five leading technical platforms at home and abroad, including strain technology platform, recombinant protein drug industrialization technology platform, microecological preparation research and development and industrialization technology platform, recombinant protein secretion and expression technology platform and long-term recombinant protein technology platform.
The company's technology center was recognized as "Shandong Provincial Enterprise Technology Center" in 217, "Jinan protein Pharmaceutical Engineering Laboratory" in 218, "Guangdong Genetic Engineering Recombinant Protein Pharmaceutical Engineering Technology Center", "Shandong protein Pharmaceutical Engineering Laboratory" and "Shenzhen Postdoctoral Innovation Practice Base" in 22. The company has obtained 38 patents and 9 biopharmaceutical projects under research, including 3 bio-innovative drugs.